359 related articles for article (PubMed ID: 17005202)
1. CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration.
Yasui K; Inoue Y; Kanbayashi T; Nomura T; Kusumi M; Nakashima K
J Neurol Sci; 2006 Dec; 250(1-2):120-3. PubMed ID: 17005202
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson's disease.
Asai H; Hirano M; Furiya Y; Udaka F; Morikawa M; Kanbayashi T; Shimizu T; Ueno S
Clin Neurol Neurosurg; 2009 May; 111(4):341-4. PubMed ID: 19097685
[TBL] [Abstract][Full Text] [Related]
3. Normal CSF hypocretin-1 (orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness.
Baumann CR; Dauvilliers Y; Mignot E; Bassetti CL
Eur Neurol; 2004; 52(2):73-6. PubMed ID: 15256827
[TBL] [Abstract][Full Text] [Related]
4. Altered CSF orexin and α-synuclein levels in dementia patients.
Wennström M; Londos E; Minthon L; Nielsen HM
J Alzheimers Dis; 2012; 29(1):125-32. PubMed ID: 22207004
[TBL] [Abstract][Full Text] [Related]
5. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy.
Borroni B; Malinverno M; Gardoni F; Alberici A; Parnetti L; Premi E; Bonuccelli U; Grassi M; Perani D; Calabresi P; Di Luca M; Padovani A
Neurology; 2008 Nov; 71(22):1796-803. PubMed ID: 18971445
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia.
Compta Y; Santamaria J; Ratti L; Tolosa E; Iranzo A; Muñoz E; Valldeoriola F; Casamitjana R; Ríos J; Marti MJ
Brain; 2009 Dec; 132(Pt 12):3308-17. PubMed ID: 19858078
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
[TBL] [Abstract][Full Text] [Related]
8. Hypocretin (orexin) loss in Parkinson's disease.
Fronczek R; Overeem S; Lee SY; Hegeman IM; van Pelt J; van Duinen SG; Lammers GJ; Swaab DF
Brain; 2007 Jun; 130(Pt 6):1577-85. PubMed ID: 17470494
[TBL] [Abstract][Full Text] [Related]
9. [Excessive daytime sleepiness and low CSF orexin-A/hypocretin-I levels in a patient with probable progressive supranuclear palsy].
Hattori Y; Hattori T; Mukai E; Mori H; Mizuno Y; Kayukawa Y; Okada T; Kanbayashi T
No To Shinkei; 2003 Dec; 55(12):1053-6. PubMed ID: 14870576
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
[TBL] [Abstract][Full Text] [Related]
11. Progressive dopamine and hypocretin deficiencies in Parkinson's disease: is there an impact on sleep and wakefulness?
Wienecke M; Werth E; Poryazova R; Baumann-Vogel H; Bassetti CL; Weller M; Waldvogel D; Storch A; Baumann CR
J Sleep Res; 2012 Dec; 21(6):710-7. PubMed ID: 22747735
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
[TBL] [Abstract][Full Text] [Related]
13. Narcolepsy in Parkinson's disease.
Haq IZ; Naidu Y; Reddy P; Chaudhuri KR
Expert Rev Neurother; 2010 Jun; 10(6):879-84. PubMed ID: 20518604
[TBL] [Abstract][Full Text] [Related]
14. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
15. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.
Holmberg B; Rosengren L; Karlsson JE; Johnels B
Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid hypocretin-1 levels in multiple system atrophy.
Martinez-Rodriguez JE; Seppi K; Cardozo A; Iranzo A; Stampfer-Kountchev M; Wenning G; Tolosa E; Högl B; Santamaria J; Poewe W;
Mov Disord; 2007 Sep; 22(12):1822-4. PubMed ID: 17659646
[TBL] [Abstract][Full Text] [Related]
17. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system.
Nishino S; Kanbayashi T
Sleep Med Rev; 2005 Aug; 9(4):269-310. PubMed ID: 16006155
[TBL] [Abstract][Full Text] [Related]
18. CSF orexin-A/hypocretin-1 concentrations in patients with intracerebral hemorrhage (ICH).
Dohi K; Ripley B; Fujiki N; Ohtaki H; Yamamoto T; Goto Y; Nakamachi T; Shioda S; Aruga T; Nishino S
Regul Pept; 2008 Jan; 145(1-3):60-4. PubMed ID: 17868933
[TBL] [Abstract][Full Text] [Related]
19. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
Mollenhauer B; Steinacker P; Bahn E; Bibl M; Brechlin P; Schlossmacher MG; Locascio JJ; Wiltfang J; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
Neurodegener Dis; 2007; 4(5):366-75. PubMed ID: 17622779
[TBL] [Abstract][Full Text] [Related]
20. Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders.
Constantinescu R; Rosengren L; Johnels B; Zetterberg H; Holmberg B
Parkinsonism Relat Disord; 2010 Feb; 16(2):142-5. PubMed ID: 19647470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
